Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy

Theranostics. 2019 May 31;9(13):3687-3706. doi: 10.7150/thno.33684. eCollection 2019.

Abstract

Increasing evidence has implicated the important role of mitochondrial pathology in diabetic cardiomyopathy (DCM), while the underlying mechanism remains largely unclear. The aim of this study was to investigate the role of mitochondrial dynamics in the pathogenesis of DCM and its underlying mechanisms. Methods: Obese diabetic (db/db) and lean control (db/+) mice were used in this study. Mitochondrial dynamics were analyzed by transmission electron microscopy in vivo and by confocal microscopy in vitro. Results: Diabetic hearts from 12-week-old db/db mice showed excessive mitochondrial fission and significant reduced expression of Mfn2, while there was no significant alteration or slight change in the expression of other dynamic-related proteins. Reconstitution of Mfn2 in diabetic hearts inhibited mitochondrial fission and prevented the progression of DCM. In an in-vitro study, cardiomyocytes cultured in high-glucose and high-fat (HG/HF) medium showed excessive mitochondrial fission and decreased Mfn2 expression. Reconstitution of Mfn2 restored mitochondrial membrane potential, suppressed mitochondrial oxidative stress and improved mitochondrial function in HG/HF-treated cardiomyocytes through promoting mitochondrial fusion. In addition, the down-regulation of Mfn2 expression in HG/HF-treated cardiomyocytes was induced by reduced expression of PPARα, which positively regulated the expression of Mfn2 by directly binding to its promoter. Conclusion: Our study provides the first evidence that imbalanced mitochondrial dynamics induced by down-regulated Mfn2 contributes to the development of DCM. Targeting mitochondrial dynamics by regulating Mfn2 might be a potential therapeutic strategy for DCM.

Keywords: Diabetic cardiomyopathy; Mfn2; Mitochondrial dynamics; Mitochondrial dysfunction; PPARα.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Cardiomegaly
  • Diabetic Cardiomyopathies / drug therapy*
  • Diabetic Cardiomyopathies / genetics*
  • Diet, High-Fat
  • Down-Regulation / drug effects
  • Fibrosis
  • GTP Phosphohydrolases / genetics*
  • GTP Phosphohydrolases / metabolism
  • Glucose / toxicity
  • Membrane Potential, Mitochondrial / drug effects
  • Mice
  • Mitochondrial Dynamics* / drug effects
  • Myocardium / pathology
  • Myocardium / ultrastructure
  • Myocytes, Cardiac / metabolism
  • Oxidative Stress
  • PPAR alpha / metabolism
  • Promoter Regions, Genetic / genetics
  • Protein Binding / drug effects
  • Rats

Substances

  • PPAR alpha
  • GTP Phosphohydrolases
  • Mfn2 protein, mouse
  • Glucose